Keiji Sugiyama

719 total citations
44 papers, 443 citations indexed

About

Keiji Sugiyama is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Keiji Sugiyama has authored 44 papers receiving a total of 443 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 13 papers in Surgery. Recurrent topics in Keiji Sugiyama's work include Gastric Cancer Management and Outcomes (17 papers), Colorectal Cancer Treatments and Studies (7 papers) and Nutrition and Health in Aging (5 papers). Keiji Sugiyama is often cited by papers focused on Gastric Cancer Management and Outcomes (17 papers), Colorectal Cancer Treatments and Studies (7 papers) and Nutrition and Health in Aging (5 papers). Keiji Sugiyama collaborates with scholars based in Japan, United Kingdom and United States. Keiji Sugiyama's co-authors include Yukiya Narita, Kei Muro, Shigenori Kadowaki, Takashi Ura, Seiichiro Mitani, Masashi Ando, Toshiki Masuishi, Kazunori Honda, Hiroya Taniguchi and Masahiro Tajika and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Keiji Sugiyama

32 papers receiving 435 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Keiji Sugiyama Japan 11 136 121 103 76 74 44 443
Sara Ekberg Sweden 15 197 1.4× 85 0.7× 28 0.3× 72 0.9× 42 0.6× 50 514
Pascal Chaı̈bi France 12 165 1.2× 94 0.8× 39 0.4× 83 1.1× 73 1.0× 33 528
Ceri Hirst United Kingdom 15 71 0.5× 74 0.6× 33 0.3× 176 2.3× 62 0.8× 28 573
Güngör Utkan Türkiye 11 227 1.7× 94 0.8× 23 0.2× 24 0.3× 62 0.8× 61 412
Andres F. Espinoza United States 10 88 0.6× 67 0.6× 92 0.9× 15 0.2× 21 0.3× 41 408
Shuyi Wei China 11 108 0.8× 51 0.4× 19 0.2× 26 0.3× 84 1.1× 31 501
Diana Chirovsky United States 11 169 1.2× 132 1.1× 36 0.3× 26 0.3× 53 0.7× 43 461
F. Binder-Foucard France 6 165 1.2× 68 0.6× 23 0.2× 19 0.3× 73 1.0× 12 365
Geoff D.E. Cuvelier Canada 13 86 0.6× 65 0.5× 11 0.1× 44 0.6× 65 0.9× 49 651
Annette Conrads‐Frank United States 11 64 0.5× 27 0.2× 152 1.5× 22 0.3× 98 1.3× 38 476

Countries citing papers authored by Keiji Sugiyama

Since Specialization
Citations

This map shows the geographic impact of Keiji Sugiyama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keiji Sugiyama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keiji Sugiyama more than expected).

Fields of papers citing papers by Keiji Sugiyama

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keiji Sugiyama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keiji Sugiyama. The network helps show where Keiji Sugiyama may publish in the future.

Co-authorship network of co-authors of Keiji Sugiyama

This figure shows the co-authorship network connecting the top 25 collaborators of Keiji Sugiyama. A scholar is included among the top collaborators of Keiji Sugiyama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keiji Sugiyama. Keiji Sugiyama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sugiyama, Keiji & Ian Chau. (2025). Claudins as diagnostic tools and therapeutic targets—Glimpse of the horizon. Cancer Treatment Reviews. 133. 102888–102888.
2.
Sugiyama, Keiji, Naureen Starling, & Ian Chau. (2025). New Horizons with Growth Differentiation Factor 15 in Oncology: From Cancer Cachexia and Tumour Immunity to Novel Therapeutic Strategies. Current Oncology. 32(11). 604–604.
3.
Kodama, Hiroko, Yukiya Narita, Michio Nakamura, et al.. (2025). A multicenter, prospective, observational study of nivolumab readministration for advanced gastric cancer (NIVO RETURNS). Future Oncology. 21(14). 1753–1759.
4.
5.
6.
Taniguchi, Toshibumi, Tomoyuki Homma, Yoichi Tamai, et al.. (2024). Clinical characteristics and COVID-19-related outcomes of immunocompromised patients receiving tixagevimab/cilgavimab pre-exposure prophylaxis in Japan. Journal of Infection and Chemotherapy. 31(1). 102467–102467.
7.
Sugiyama, Keiji, et al.. (2021). Efficacy of trastuzumab deruxtecan in an advanced gastric cancer patient with brain metastasis. Current Problems in Cancer. 45(6). 100757–100757. 6 indexed citations
8.
Sugiyama, Keiji, et al.. (2021). The impact of nutrition support in advanced gastric adenocarcinoma patients treated with chemotherapy.. Journal of Clinical Oncology. 39(3_suppl). 208–208. 1 indexed citations
9.
Sugiyama, Keiji, Kazuki Nozawa, Yoshihito Kogure, et al.. (2019). Primary Mediastinal HER2-positive Apocrine Carcinoma in Mature Teratoma Treated With Anti-HER2 Therapy and Chemoradiation. In Vivo. 33(2). 551–557. 1 indexed citations
10.
Honda, Kazunori, Bishal Gyawali, Masashi Ando, et al.. (2018). A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study. ecancermedicalscience. 12. 847–847. 43 indexed citations
11.
Sugiyama, Keiji, Yukiya Narita, Seiichiro Mitani, et al.. (2018). Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer. Anticancer Research. 38(10). 5859–5866. 48 indexed citations
12.
Masuishi, Toshiki, Hiroya Taniguchi, Satoshi Hamauchi, et al.. (2017). Efficacy of bevacizumab in combination with doublet chemotherapy as first-line therapy in metastatic colorectal cancer according to KRAS status.. Journal of Clinical Oncology. 35(4_suppl). 744–744. 1 indexed citations
13.
Sugiyama, Keiji, Yukiya Narita, Shigenori Kadowaki, et al.. (2017). Platinum-based Doublet Chemotherapy for Advanced Gastric Cancer with Disseminated Intravascular Coagulation. Anticancer Research. 37(1). 309–314. 9 indexed citations
14.
Fujimaki, Takamitsu, K Itoh, Mizuhiko Terasaki, et al.. (2017). P07.02 Trials of a personalized peptide vaccine (ITK-1) for patients with recurrent or progressive glioblastoma (GBM). Neuro-Oncology. 19(suppl_3). iii52–iii52. 2 indexed citations
15.
Sugiyama, Keiji, Yuta Hasegawa, Hiroyuki Nakamura, et al.. (2016). The efficacy and safety of re-administration of rasburicase for patients with hematological malignancies. Annals of Oncology. 27. vii100–vii100.
16.
Ledent, Edouard, et al.. (2016). Post-Marketing Benefit–Risk Assessment of Rotavirus Vaccination in Japan: A Simulation and Modelling Analysis. Drug Safety. 39(3). 219–230. 15 indexed citations
17.
Hirao, Maki, Yuiko Tsukada, Takahide Kikuchi, et al.. (2013). Primary HER2-Positive Lacrimal SAC Cancer. Annals of Oncology. 24. ix84–ix84. 1 indexed citations
18.
Nagane, Motoo, Ryo Nishikawa, Yusuke Narita, et al.. (2012). Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma. Japanese Journal of Clinical Oncology. 42(10). 887–895. 70 indexed citations
19.
Sato, Takahiro, Goshi Nishimura, Yutaka Yonemura, et al.. (1995). Association of Immunohistochemical Detection of Urokinase-Type Plasminogen Activator with Metastasis and Prognosis in Colorectal Cancer. Oncology. 52(4). 347–352. 26 indexed citations
20.
Sugiyama, Keiji, et al.. (1992). [A case of gallbladder cancer with marked response to EAP treatment].. PubMed. 19(6). 897–900. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sara Ekberg Breakdown of academic impact, for papers by Pascal Chaı̈bi Breakdown of academic impact, for papers by Ceri Hirst Breakdown of academic impact, for papers by Güngör Utkan Breakdown of academic impact, for papers by Andres F. Espinoza Breakdown of academic impact, for papers by Shuyi Wei Breakdown of academic impact, for papers by Diana Chirovsky Breakdown of academic impact, for papers by F. Binder-Foucard Breakdown of academic impact, for papers by Geoff D.E. Cuvelier Breakdown of academic impact, for papers by Annette Conrads‐Frank
Rankless by CCL
2026